Metabolic Syndrome in a Rural Nigerian Community: Is Central Obesity always the key Determinant?

Authors

  • Iyeopu Siminalayi Department of Pharmacology,College of Health Sciences, University of Port Harcourt, Rivers State
  • Pedro Chimezie Emem-Chioma Department Internal Medicine, College of Health Sciences, University of Port Harcourt, Rivers State

Keywords:

Metabolic syndrome, rural community, Nigeria

Abstract

Background: Metabolic syndrome (MS) is primarily the consequence of excess central adiposity but can also result from low grade systemic inflammation inducing insulin resistance. There is a global increase in the prevalence of MS; it is on this background that evaluation of the prevalence of MS in a poor rural farming community with a low expected low prevalence of obesity is relevant. The objective of this study was to determine the prevalence of metabolic syndrome using the National Cholesterol Education Project: Adult Treatment Panel III definition (MS-ATP) in a rural Nigerian community.

Methods: 300 adult consenting participants were bled after an overnight fast, and venous blood obtained for lipid studies and fasting blood glucose estimation. Measurements were made to determine height, weight, waist circumference and blood pressure. The prevalence of each diagnostic component was determined and the relative risk (RR) of each component for MS-ATP was calculated.

Results: The prevalence of MS-ATP was 6.30%, central obesity 5.33% (RR = 3 .3 [95% CI: 1.08-1 0.26]), and hypertriglyceridaemia 11.33% (RR=21.91[95% CI:8.42- 57.32]). The prevalence of low HDL-cholesterol was highest (85.67%) but the RR was not calculable.

Conclusion: Unlike previous reports the prevalence of central obesity was very low in this study and contributed little to the development of MS-ATP. Hypertriglyceridaemia appears to be associated with the greatest risk of developing metabolic syndrome in this community while Low HDL- cholesterol although most prevalent is a poor diagnostic requirement for metabolic syndrome

Author Biographies

Iyeopu Siminalayi, Department of Pharmacology,College of Health Sciences, University of Port Harcourt, Rivers State

Senior Lecturer in Pharmacology

Pedro Chimezie Emem-Chioma, Department Internal Medicine, College of Health Sciences, University of Port Harcourt, Rivers State

Lecturer and Consultant Nephrologist

References

Grundy SM. Controversy in clinical endocrinology. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007; 92(2), 399-404.

Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365(9468) 1415-1428.

Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366(9491), 1059-1062.

Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005; 35(1), 8-17.

Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-a: direct role in obesity-linked insulin resistance. Science 1993; 259(5091), 87-91.

Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1 mediated inhibition ofinsulin receptor tyrosine kinase activity in TNF-a- and obesity-induced insulin resistance. Science 1996; 271(5249), 665-668.

Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002; 277(44), 42394-42398.

Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109(23), 2818-2825.

Gabriel SE, Crowson CS, O'Fallen WM: Comorbidity in arthritis. J Rheumatol 1994; 26(11), 2475-2479.

Del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44(12), 2737-2745.

Solomon DH, Karlson EW, Rimm EB et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107(9), 1030-1307.

Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003; 30(1), 36-40.

Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102(1), 42-47.

Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome. A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111(11), 1448-1454.

Gami AS, Witt BJ, Howard DE et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis oflongitudinal studies. J Am Coll Cardiol 2007; 49(4), 403-414.

Fezau L, Balkau B, Kegne A-P, Sobngwa E, Mbonya J-C. Metabolic syndrome in a sub-Saharan African setting: central obesity may be the key determinant. Atherosclerosis 2007; 193(1): 70-76.

Isezuo SA. Is high density lipoprotein cholesterol useful in diagnosis of metabolic syndrome in native Africans with type 2 diabetes? Ethn Dis 2005; 15: 6-10.

Siminialayi IM, Emem-Chioma PC, Odia OJ. Relative risk of metabolic syndrome components in Nigerians: the adult treatment III definition. PMJ 2009; 3: 302-311.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, et al. Diagnosis and management of metabolic syndrome. Circulation2005; 112: 2735-2752.

World Health Organization (WHO). Blood safety and clinical technology: guidelines on standard operating procedures for clinical chemistry. Available at: http://www.searo.who.int/EN/Section10/Section17/Section53/Section481_1753.htm Accessed March 17, 2007.

Emeis JJ, van Gent CM, van Sabben CM. An enzymatic method for the histochemical localization of free esterified cholesterol separately. The Histochem J 1977; 9: 197-204.

Gibbons VB, Ballantyne FC. Triglyceride estimation in high density lipoproteins. Med Lab Sci 1981; 38: 277-279.

Dessein PH, Gonzalez-Gay MA, Woodwiss AJ, Joffe BI, Norton GR, Solomon A. The impact of metabolic syndrome on cardiovascular risk factors and disease in rheumatoid arthritis. Future Rheumatol 2008; 3(4):335-349.

Grundy SM. Does a diagnosis of metabolic syndrome have value in clinical practice? Am J Clin Nutr 2006; 83(6), 1248-1251.

Reaven GM. Role of insulin resistance in human disease. Diabetes 37(12), 1595-1607 (1988).

Akinkugbe OO, ed. Non-communicable diseases in Nigeria: final report of a national survey. Federal Ministry of Health (Nigeria) 1997; 4: 5-118.

Downloads

Published

2015-11-29

How to Cite

Siminalayi, I., & Emem-Chioma, P. C. (2015). Metabolic Syndrome in a Rural Nigerian Community: Is Central Obesity always the key Determinant?. The Nigerian Health Journal, 8(3 - 4), 48. Retrieved from https://tnhjph.com/index.php/tnhj/article/view/15

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.